LicMABs, generated by grafting the endogenous N-terminal extracellular domain of SIRPα onto an IgG1 antibody targeting the AML antigen CD33, successfully induced NK cell-mediated killing of AML cell lines and primary AML patient cells and enhanced phagocytosis of AML cell lines. The gene discussed is CD33; the disease is acute myeloid leukemia.